CSF-1 Overview

ORASIS PHARMACEUTICALS COMPLETED TWO PHASE 3 U.S. STUDIES, NEAR-1 AND NEAR-2, WHICH
EVALUATED THE EFFICACY AND SAFETY OF CSF-1.

To find out more about NEAR-1 and NEAR-2,

visit clinicaltrials.gov: NEAR-1, NEAR-2

CSF-1 IS A NOVEL PRESBYOPIA CORRECTIVE EYE DROP

being developed to improve the quality of life for people with presbyopia by providing an alternative to reading glasses. CSF-1 is a preservative-free solution that contains a proprietary combination of low-dose pilocarpine and multi-faceted vehicle. Our solution aims for the optimal balance between efficacy, safety and comfort with the potential to improve near vision in people with presbyopia.

CSF-1 WAS DESIGNED WITH THE PATIENT IN MIND

Clinical trial results to date have demonstrated significant improvements in near vision and an excellent safety profile in people with presbyopia. In our Phase 3 studies, CSF-1 achieved statistically significant distance-corrected near visual acuity (DCNVA) and no loss of 1-line or more in distance or night vision. Please see our press release to learn more about our Phase 3 topline results.